Walpar Nutritions Ltd
Incorporated in 2009, Walpar Nutritions Ltd manufactures and trades Pharmaceutical, Nutraceutical, Herbal and Ayurvedic commodities[1]
- Market Cap ₹ 42.7 Cr.
- Current Price ₹ 45.5
- High / Low ₹ 53.3 / 37.7
- Stock P/E 27.0
- Book Value ₹ 17.0
- Dividend Yield 0.00 %
- ROCE 17.6 %
- ROE 11.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 55.2 days to 39.1 days
Cons
- Stock is trading at 2.67 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.07% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 1m | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 16.71 | 1.43 | 6.07 | 26.76 | 28.70 | 51.31 | 60.16 | 63.97 | |
| 15.50 | 1.05 | 5.61 | 25.68 | 27.92 | 49.54 | 57.32 | 61.30 | |
| Operating Profit | 1.21 | 0.38 | 0.46 | 1.08 | 0.78 | 1.77 | 2.84 | 2.67 |
| OPM % | 7.24% | 26.57% | 7.58% | 4.04% | 2.72% | 3.45% | 4.72% | 4.17% |
| 0.00 | 0.00 | 0.00 | 0.02 | 0.27 | 0.13 | 0.10 | 0.15 | |
| Interest | 0.73 | 0.05 | 0.18 | 0.48 | 0.34 | 0.21 | 0.10 | 0.06 |
| Depreciation | 0.29 | 0.02 | 0.12 | 0.28 | 0.25 | 0.21 | 0.41 | 0.47 |
| Profit before tax | 0.19 | 0.31 | 0.16 | 0.34 | 0.46 | 1.48 | 2.43 | 2.29 |
| Tax % | 36.84% | 25.81% | 6.25% | -26.47% | 34.78% | 24.32% | 30.45% | |
| 0.12 | 0.23 | 0.15 | 0.42 | 0.29 | 1.11 | 1.69 | 1.58 | |
| EPS in Rs | 0.38 | 0.22 | 0.46 | 0.32 | 1.18 | 1.80 | 1.68 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 31% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 58% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 22% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 8% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.93 | 3.00 | 3.34 | 4.54 | 4.54 | 4.70 | 9.39 | 9.39 |
| Reserves | 0.00 | 0.23 | 1.44 | 6.49 | 6.78 | 8.64 | 5.63 | 6.62 |
| 5.55 | 5.88 | 5.46 | 4.38 | 3.21 | 0.32 | 0.00 | 0.21 | |
| 5.69 | 5.44 | 5.45 | 7.95 | 7.33 | 9.84 | 15.90 | 18.85 | |
| Total Liabilities | 13.17 | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 | 35.07 |
| 1.12 | 1.15 | 1.07 | 0.94 | 0.83 | 1.48 | 2.29 | 2.49 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 | 0.04 |
| Investments | 0.00 | 0.00 | 0.06 | 2.93 | 2.84 | 4.70 | 4.70 | 5.06 |
| 12.05 | 13.40 | 14.56 | 19.49 | 18.17 | 17.30 | 23.90 | 27.48 | |
| Total Assets | 13.17 | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 | 35.07 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -0.76 | 0.40 | 1.38 | -0.32 | 1.09 | 3.13 | 2.71 | |
| -0.66 | 0.00 | -0.70 | -4.58 | 0.46 | -0.88 | -1.23 | |
| 1.07 | -0.24 | -0.06 | 4.27 | -1.52 | -2.18 | -0.42 | |
| Net Cash Flow | -0.35 | 0.17 | 0.62 | -0.63 | 0.03 | 0.07 | 1.06 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 160.55 | 2,141.50 | 430.54 | 124.26 | 111.66 | 71.78 | 102.84 |
| Inventory Days | 130.73 | 1,690.75 | 369.26 | 103.22 | 89.87 | 39.99 | 32.83 |
| Days Payable | 186.46 | 2,156.44 | 434.08 | 130.02 | 99.69 | 67.10 | 93.80 |
| Cash Conversion Cycle | 104.82 | 1,675.81 | 365.73 | 97.45 | 101.84 | 44.67 | 41.87 |
| Working Capital Days | 60.07 | 1,028.64 | 268.79 | 79.79 | 79.99 | 46.31 | 39.13 |
| ROCE % | 3.84% | 6.55% | 5.34% | 11.56% | 17.64% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Domestic Sales Revenue Rs. in Lakhs |
|
||||
| Employee Benefit Expenses Rs. in Lakhs |
|||||
| Export Sales Revenue Rs. in Lakhs |
|||||
| Trade Receivables Turnover Ratio times |
|||||
Documents
Announcements
-
Outcome of Board Meeting
20 March 2026 - Board approved corporate guarantee to SIDBI for Walpar Wellness's Rs.5,64,05,000 term loan (20 Mar 2026).
-
Updates
20 January 2026 - Walpar Nutritions: governance provisions not applicable for quarter ended 31 Dec 2025 due to SME listing.
-
Structural Digital Database
9 January 2026 - Submitted SDD compliance certificates for quarter ended 31 Dec 2025; one event captured; no non-compliance.
-
Clarification - Financial Results
8 January 2026 - Exchange has sought clarification from Walpar Nutritions Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
6 January 2026 - RTA certifies no physical share certificates received for demat for quarter ended 31-Dec-2025.
Business Overview:[1]
Company manufactures and sells Nutraceutical and Herbal dietary supplement formulations, ingredients and research. It manufactures private label brands for different companies and its own brands, selling through online and direct channels. Company is a specialized Contract manufacturer for different formulation in Nutraceuticals and Herbal products